Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 12/20 | 0.42 |
| ▸ | CDK2 | P24941 | 12/20 | 0.42 |
| ▸ | CDK4 | P11802 | 11/20 | 0.42 |
| ▸ | CCND1 | P24385 | 11/20 | 0.42 |
| ▸ | JUN | P05412 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | CASK | O14936 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.39 |
| ▸ | STK10 | O94804 | 1/20 | 0.39 |
| ▸ | CDK14 | O94921 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | MAK | P20794 | 1/20 | 0.39 |
| ▸ | CDK11B | P21127 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334531 | 1.00 | PDE10A (0.44) | PDE10AGRM5CDK1CDK2CDK4 | |
| SCHEMBL1332875 | 0.81 | GRM5 (0.43) | PDE10AGRM5CDK1CDK2CDK4 | |
| SCHEMBL1332877 | 0.81 | GRM5 (0.43) | PDE10AGRM5CDK1CDK2CDK4 | |
| SCHEMBL3418540 | 0.81 | GRM5 (0.43) | GRM5CDK1CDK2CDK4CCND1 | |
| SCHEMBL3418538 | 0.81 | GRM5 (0.43) | GRM5CDK1CDK2CDK4CCND1 | |
| SCHEMBL1034813 | 0.80 | GRM5 (0.48) | GRM5CDK1CDK2CDK4CCND1 | |
| SCHEMBL1034814 | 0.80 | GRM5 (0.48) | GRM5CDK1CDK2CDK4CCND1 | |
| SCHEMBL1334198 | 0.79 | CDK4 (0.43) | PDE10AGRM5CDK1CDK2CDK4 | |
| SCHEMBL1334197 | 0.79 | CDK4 (0.43) | PDE10AGRM5CDK1CDK2CDK4 | |
| SCHEMBL1333315 | 0.78 | MAPK8 (0.47) | GRM5CDK1CDK2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513242-B2 | Pyrimidine compounds and methods of making and using same | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CYSTIC FIBROSIS FOUNDATION | 2011-11-17 | — | — | US | disclosed |
| WO-2010068863-A2 | PYRIMIDINE COMPOUNDS AND METHODS OF MAKING AND USING SAME | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CFTR, GPR17, TYMS | PDE10A 707/4885GRM5 2764/4885CDK1 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.